New Daily Persistent Headache
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Prevail TherapeuticsNY - New York
1 programNew Daily Persistent Headache Biomarkers StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieOnabotulinumtoxinA
Prevail TherapeuticsNew Daily Persistent Headache Biomarkers Study
Clinical Trials (2)
Total enrollment: 14 patients across 2 trials
OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study
Start: Sep 2014Est. completion: Oct 20166 patients
Phase 2Terminated
New Daily Persistent Headache Biomarkers Study
Start: May 2018Est. completion: Nov 20218 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.